Inpart (Industry Partnering Platform)

**What it means:** Inpart is a **global scientific partnering platform** used by 90% of the world's top 50 pharmaceutical companies. Think of it as LinkedIn for drug development — it tracks which academic discoveries and technologies are attracting the most attention from pharma companies. Research is ranked based on real-world engagement: how many pharma companies are requesting partnerships, making direct inquiries, or investing time in the research. **Why the top-10 ranking matters:** Being in the top 10 for "most impactful early-stage innovations" is a **massive deal** for an academic lab working on a rare disease. It means the world's biggest drug companies are actively interested in this research. This dramatically increases the chances that the therapy will eventually be developed to clinical trials and to market. It's not just academic recognition — it's a signal that the commercial pathway is becoming real.